Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666497 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00666497: Clinical Trial Phase 2 study, sponsored by Mirati Therapeutics.
NCT00666497 is a Phase 2 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666497, a Phase 2 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.
Interventions
- DRUG Azacitidine
- DRUG MGCD0103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Why NCT00666497 stopped before completion
NCT00666497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT00666497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00666497 about?
NCT00666497 is a clinical study titled "Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)". The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.
What is the current status of trial NCT00666497?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00666497?
The interventions under investigation include: Azacitidine (DRUG), MGCD0103 (DRUG).
Who is sponsoring clinical trial NCT00666497?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00666497's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia